BRCA Germline
BRCA Germline test detects gene mutations that are passed down from generation to generation (genetic variants) and involved in the inherited cancer susceptibility. A simple blood or saliva sample is required and it is performed once in a person’s lifetime
BRCA Germline test provides important information that can:
Assist physicians choose the best individualised treatment for reducing the risk of cancer development in healthy carriers of the pathogenic mutation or the recurrence in the already diseased.
Identifies family members carrying a pathogenic mutation and assists in their management options: more regular preventive check-ups, prophylactic surgical interventions and/or preimplantation genetic diagnosis in order to avoid the transfer of the pathogenic mutation to the offspring through IVF.
Identifies the family members who do not carry a pathogenic mutation in order to relieve stress and unnecessary interventions.
BRCA gene mutations can significantly increase the risk of breast and/or ovarian cancer
A BRCA gene mutation can increase the risk of breast cancer to up to 87% by the age of 70
7% Risk of general population
A BRCA gene mutation can increase the risk of ovarian cancer to up to 44% by the age of 70
1% Risk of general population
BRCA gene mutation
87%
BRCA gene mutation
44%
This test is considered necessary and is addressed to all women who have had breast cancer, including those with:
A personal history of breast cancer at the age of 45 or younger
A personal history of triple negative breast cancer diagnosed at the age of 60 or younger
A personal history of breast cancer at any age and a family member diagnosed with breast cancer at age 50 or younger
A personal history of breast cancer at any age and a family member diagnosed with breast, pancreatic and/or prostate cancer at any age
A personal or family history of ovarian cancer A personal or male breast cancer
A family member diagnosed with breast cancer at the age 45 or younger
BRCA GERMLINE SAMPLE REPORT
The test covers mainly breast and ovarian cancer, as it may also increase the risk of pancreatic and prostate cancer, as well as melanoma.
The results obtained by the test are useful for the entire family, as it is enough for a person to inherit a BRCA mutation from one parent, to be at increased risk of developing cancer. A child whose parent is a BRCA mutant carrier has a 50% chance of inheriting the mutation. More distant relatives are also at risk of carrying the mutation. Individuals who may be carriers of inherited BRCA gene mutation can be identified by referral for genetic testing. Note that hereditary cancer susceptibility syndromes can be associated with many different types of cancer. Therefore, a mutation detected in the sample for breast or ovarian cancer may be associated with an increased risk of pancreatic or prostate cancer.
Results will be available in 15 business days.
Whole peripheral blood in 2 EDTA vials or saliva sample in the special kit provided by our company
Payment can be made by bank transfer or debit/credit card.
For the necessary sample collection procedures, please contact us at +30 210 6032138
No, sci-pharm DOES NOT perform blood sample collections so you need to contact your doctor or any other laboratory which performs this kind of collections so you can get the sample.
For the use of the patient’s genetic material for testing, ELOT EN ISO9001:2008 and ELOT EN ISO15189:2012 require the written consent of each patient.
Your results are shared with your GP via email.
Our Customer Service Team is committed to answer your questions with regards to the services offered by sci-pharm . If you would like to order any of the tests that sci-pharm performs please contact us directly.
